The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.
Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback